Skip to content

Efficacy of the DOMINO Diet App in IBS

The Efficacy of the DOMINO Diet Application Versus the Low FODMAP Diet in Tertiary Care IBS Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05808036
Acronym
EDDI
Enrollment
110
Registered
2023-04-11
Start date
2023-04-01
Completion date
2026-08-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

DOMINO, Low FODMAP diet, Irritable bowel syndrome

Brief summary

The aim of this study is to evaluate whether the DOMINO diet application is an effective tool in the treatment of Irritable bowel syndrome in tertiary care. Furthermore, this study aims to determine the response rate of the strict low FODMAP diet in non-responders to the DOMINO diet.

Interventions

OTHERDietary intervention: DOMINO app

Life style intervention and diet low in FODMAPs.

OTHERDietary intervention: low FODMAP diet

Strict low FODMAP diet.

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All patients will start with the DOMINO diet. Depending on the symptom improvement they will continue the DOMINO diet or switch to the strict low FODMAP diet.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner. 3. Patients with irritable bowel syndrome according to Rome IV diagnostic criteria 4. Patients ages between 18 and 70 years old

Exclusion criteria

1. Participant has a history of any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years 2. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol 3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial 4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive 5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device 6. Patients presenting with predominant symptoms of functional dyspepsia (FD) and of gastro-oesophageal reflux disease (GERD) 7. Patients following a diet interfering with the study diet in opinion of the investigator 8. Patients who already followed the low FODMAP diet under guidance of a trained dietitian without success

Design outcomes

Primary

MeasureTime frameDescription
Symptom response DOMINO app and low FODMAP diet18 monthsThe symptom response is measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). In this questionnaire, each question (5) is scored from 0-100, with a maximum total score of 500. Improvement is defined as a 50-point or more drop on the IBS-SSS. The score is positively correlated with severity of IBS symptoms, a score from 50-175 indicated mild disease, 175-300 moderate and \>300 severe.

Countries

Belgium

Contacts

CONTACTJan Tack
jan.tack@kuleuven.be016344225
CONTACTKaren Routhiaux
karen.routhiaux@kuleuven.be016372847

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026